An overview of Clovis
Clovis Oncology (CLVS) is focused on bringing to market innovative anticancer agents. One of its products, Rubraca, has been approved for the treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
In July, Clovis received EMA (European Medicines Agency) approval for its application for a variation to its marketing authorization of Rubraca. The company expects an opinion from the EMA’s Committee for Medicinal Products for Human Use for this application by the end of 2018 and a potential approval from the European Commission in early 2019.
Clovis is also developing Rubraca for different types of solid tumors, such as prostate and bladder cancers. Rubraca was granted a breakthrough therapy designation by the FDA in October as a monotherapy for treating metastatic castration-resistant prostate cancer.
In this series, we’ll explore Clovis Oncology’s financials, analysts’ recommendations for the stock, and its valuation metrics.
Clovis Oncology generated total revenue of $22.76 million in the third quarter compared to $16.81 million in the comparable period of 2017. This increase was due to higher Rubraca sales during the period.
We’ll take a look at Clovis Oncology’s gross margin trend in the next article.